CD40 and neoplasm: Targeting of COX2 is also a potential therapeutic pathway to circumvent immunotherapy failure in PDAC, as COX2 tumor-specific depletion combined to anti-PD-1 and agonist CD40 antibodies significantly decreases PDAC growth and extends survival of tumor-bearing mice, while monotherapies are mostly ineffective [113].